CB Therapeutics

Founded in 2018 by Sher Butt and Jacob Vogan, Carlsbad, California-based CB Therapeutics develops precision fermentation technology using a proprietary yeast platform to produce psychedelic therapeutics, synthetic cannabinoids, tryptamines, and food tech compounds. The Y Combinator Summer 2018 alumni manufacture pure, bio-identical molecules for research, clinical trials, and commercial markets spanning neuroscience, nutraceuticals, cannabis, cosmetics, and the food and beverage sectors. By focusing on sustainable bio-manufacturing, the enterprise of eighteen employees aims to replace costly and environmentally harmful production methods with highly scalable alternatives to address physical wellness, nutrition, and scarcity challenges. To expand its commercial footprint, the company established a joint venture called TryptageniX with atai Life Sciences to generate annual recurring revenue. Guiding its clinical applications for mental health treatments, the organization appointed medical advisors Stephen Wright and Brian Barnett to its advisory board.

High-Level Overview

CB Therapeutics is a synthetic biology company that develops fermentation-derived natural products, primarily cannabinoids and tryptamines, to address mental health and addiction challenges such as depression, PTSD, opioid addiction, alcoholism, and chronic pain. Their technology leverages cellular agriculture and industrial biotechnology to sustainably and scalably produce complex therapeutic compounds traditionally extracted from plants or animals. Their primary customers include pharmaceutical companies, research organizations, and healthcare providers focused on innovative mental health treatments[1][2].

Origin Story

Founded in 2018 by Sher Butt and Jacob Vogan, both with strong backgrounds in molecular biology and aging research from UC Berkeley, CB Therapeutics emerged from the founders’ vision to engineer yeast and other microbes to produce rare wellness compounds like cannabinoids and psychedelics. This approach aimed to make these compounds more accessible and reliable than traditional extraction methods. Early traction included participation in Y Combinator and collaborations such as the launch of TryptageniX with atai Life Sciences, signaling pivotal moments in their growth[2].

Core Differentiators

• Product Differentiators: Precision synthetic biology enables the production of high-quality, rare cannabinoids and tryptamines that are difficult or costly to extract from natural sources.
• Sustainable Manufacturing: Use of fermentation and cellular agriculture allows scalable, consistent, and animal-free production.
• Broad Application: Their compounds serve diverse sectors including neuroscience, clinical research, nutraceuticals, cannabis, cosmetics, and food and beverage markets[1][3].
• Scientific Expertise: Founders’ deep expertise in molecular biology and aging underpins advanced bioengineering capabilities.
• Commercial Readiness: Actively building a state-of-the-art bio-manufacturing facility to meet growing market demand[5].

Role in the Broader Tech Landscape

CB Therapeutics rides the convergence of synthetic biology, precision fermentation, and the rising demand for novel mental health therapeutics. The timing is critical as mental health disorders and addiction crises grow globally, and traditional pharmaceutical approaches face limitations. Market forces favor sustainable, scalable biomanufacturing methods that reduce reliance on plant extraction and chemical synthesis. By enabling reliable access to rare therapeutic compounds, CB Therapeutics influences the broader ecosystem by accelerating innovation in biotech-driven mental health solutions and expanding the commercial viability of fermentation-derived natural products[1][2][3].

Quick Take & Future Outlook

Looking ahead, CB Therapeutics is poised to scale its manufacturing capabilities and expand its product portfolio, potentially entering new markets such as longevity and wellness peptides. Trends in mental health awareness, regulatory openness to cannabinoid and psychedelic therapies, and advances in synthetic biology will shape their trajectory. Their influence may grow as a key enabler of next-generation therapeutics that combine sustainability with clinical efficacy, positioning them as a leader in the emerging bioeconomy focused on health and wellness.

This aligns with their founding mission to create accessible, sustainable solutions for some of humanity’s most pressing health challenges through innovative fermentation-derived natural products.